Translation initiation factors and their relevance in cancer
- PMID: 29153484
- PMCID: PMC7269109
- DOI: 10.1016/j.gde.2017.11.001
Translation initiation factors and their relevance in cancer
Abstract
Deregulation of several translation initiation factors occurs in numerous types of cancers. Translation initiation factors are not merely ancillary players in cancer development and progression, but rather, they are key participants in cellular transformation and tumor development. In fact, the altered expression of translation initiation factors is involved in cancer cell survival, metastasis and tumor angiogenesis. Although the exact mechanisms remain to be fully characterized, translation initiation factors comprise novel targets for pharmacologic intervention. Here we review the most recently established roles of initiation factors in cancer development and progression, as well as unique methods used to study translational regulation.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer.Trends Cell Biol. 2016 Dec;26(12):918-933. doi: 10.1016/j.tcb.2016.06.005. Epub 2016 Jul 15. Trends Cell Biol. 2016. PMID: 27426745 Review.
-
Translation initiation and its relevance in colorectal cancer.FEBS J. 2021 Dec;288(23):6635-6651. doi: 10.1111/febs.15690. Epub 2021 Jan 24. FEBS J. 2021. PMID: 33382175 Free PMC article. Review.
-
eIF4E expression in tumors: its possible role in progression of malignancies.Int J Biochem Cell Biol. 1999 Jan;31(1):59-72. doi: 10.1016/s1357-2725(98)00132-0. Int J Biochem Cell Biol. 1999. PMID: 10216944 Review.
-
Translation initiation factor 4E.Int J Biochem Cell Biol. 1999 Jan;31(1):31-5. doi: 10.1016/s1357-2725(98)00129-0. Int J Biochem Cell Biol. 1999. PMID: 10216941 Review.
-
The translation factor eIF5A and human cancer.Biochim Biophys Acta. 2015 Jul;1849(7):836-44. doi: 10.1016/j.bbagrm.2015.05.002. Epub 2015 May 13. Biochim Biophys Acta. 2015. PMID: 25979826 Free PMC article. Review.
Cited by
-
Perturbations in eIF3 subunit stoichiometry alter expression of ribosomal proteins and key components of the MAPK signaling pathways.Elife. 2024 Nov 4;13:RP95846. doi: 10.7554/eLife.95846. Elife. 2024. PMID: 39495207 Free PMC article.
-
Loss-of-function cancer-linked mutations in the EIF4G2 non-canonical translation initiation factor.Life Sci Alliance. 2023 Dec 21;7(3):e202302338. doi: 10.26508/lsa.202302338. Print 2024 Mar. Life Sci Alliance. 2023. PMID: 38129098 Free PMC article.
-
Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness.Front Oncol. 2019 Dec 6;9:1311. doi: 10.3389/fonc.2019.01311. eCollection 2019. Front Oncol. 2019. PMID: 31867270 Free PMC article.
-
Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma.Int J Mol Sci. 2023 Mar 3;24(5):4885. doi: 10.3390/ijms24054885. Int J Mol Sci. 2023. PMID: 36902316 Free PMC article. Review.
-
A DAP5/eIF3d alternate mRNA translation mechanism promotes differentiation and immune suppression by human regulatory T cells.Nat Commun. 2021 Nov 30;12(1):6979. doi: 10.1038/s41467-021-27087-w. Nat Commun. 2021. PMID: 34848685 Free PMC article.
References
-
- Lane N, Martin W: The energetics of genome complexity. Nature 2010, 467:929–934. - PubMed
-
- Chu J, Cargnello M, Topisirovic I, Pelletier J: Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer. Trends Cell Biol 2016, 26:918–933. - PubMed
-
- Silvera D, Formenti SC, Schneider RJ: Translational control in cancer. Nat Rev Cancer 2010, 10:254–266. - PubMed
-
- Sendoel A, Dunn JG, Rodriguez EH, Naik S, Gomez NC, Hurwitz B, Levorse J, Dill BD, Schramek D, Molina H, et al.: Translation from unconventional 5′ start sites drives tumour initiation. Nature 2017, 541:494–499. - PMC - PubMed
-
This article uses ribosome footprinting to identify translation from unconventional 5’ start sites as a mechanism driving tumor initiation.
-
- Demosthenous C, Han JJ, Stenson MJ, Maurer MJ, Wellik LE, Link B, Hege K, Dogan A, Sotomayor E, Witzig T, et al.: Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget 2015, 6:9488–9501. - PMC - PubMed
-
This article highlights the importance of the regulation of the eIF4F complex in aggressive lymphoma as well as demonstrating the therapeutic potential of dual mTOR therapies.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources